Acurx Pharmaceuticals, Inc. (ACXP)
Nasdaq · Healthcare · Biotechnology
$1.31+3.15%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.3M
- 52-week range
- $1.23 – $8.34
- 52-week change
- −70.33%
- EPS (trailing)
- −$2.67
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$8.0M
- Diluted EPS
- −$5.32
From the company’s annual report on SEC EDGAR.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Headquarters: Staten Island, United States · 4 employees · acurxpharma.com